Suchergebnisse - "Fehn, Karen"

PubPharm (9)

1

Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer

enthalten in: Clinical breast cancer | 2018

von Anampa, J. | Chen, A. | Wright, J. | +5

2

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

enthalten in: Breast cancer research and treatment | 2014

von Tu, Y. | Hershman, D. | Bhalla, K. | +13

3

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

enthalten in: Breast cancer research and treatment | 2014

von Tu, Y. | Hershman, D. | Bhalla, K. | +13

4

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

enthalten in: Breast cancer research and treatment | 2014

von Tu, Y. | Hershman, D. | Bhalla, K. | +13

5

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer

enthalten in: Breast cancer research and treatment | 2014

von Tu, Y. | Hershman, D. | Bhalla, K. | +13

6

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

enthalten in: Breast cancer research and treatment | 2013

von Andreopoulou, E. | Vigoda, I. | Valero, V. | +11

7

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

enthalten in: Breast cancer research and treatment | 2013

von Andreopoulou, E. | Vigoda, I. | Valero, V. | +11

8

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

enthalten in: Breast cancer research and treatment | 2013

von Andreopoulou, E. | Vigoda, I. | Valero, V. | +11

9

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

enthalten in: Breast cancer research and treatment | 2013

von Andreopoulou, E. | Vigoda, I. | Valero, V. | +11

1
[1]